A breast cancer pathology report can feel overwhelming, especially when you see unfamiliar terms such as ER, PR, IHC, and HER2. Your ER and PR results show whether hormones may be helping breast cancer cells grow, which can affect your cancer treatment plan.
For patients and families in Malaysia, these results are an important part of a cancer diagnosis. They describe part of the tumour’s overall hormone receptor status but never stand alone. Your oncologist interprets them with the tumour size, grade, lymph nodes, scans, HER2 status, cancer stage, and your overall health.
Quick Answer: What ER and PR Results Tell You
ER means estrogen receptor, while PR means progesterone receptor. These receptors are proteins inside some breast cancer cells. When present, estrogen or progesterone may help those cells grow.
ER and PR results classify a tumour’s hormone receptor status. A tumour is hormone receptor-positive if ER, PR, or both are positive. This may support discussion of hormone therapy as part of your breast cancer treatment.
A tumour is hormone receptor negative when both tests are negative. This result alone doesn’t determine the complete treatment plan, so your team will discuss other treatment options based on the full diagnosis.
Malaysia’s breast cancer clinical practice guideline recommends assessing ER and PR status in all breast cancers.
5 Key Takeaways
- ER and PR testing examines a tissue sample, usually collected during a breast biopsy or surgery. A core needle biopsy is common, while fine needle aspiration may provide less tissue detail for receptor testing.
- ER and PR results help determine the tumour’s hormone receptor status. At least 1% tumour-cell staining is generally reported as positive for either receptor.
- ER-positive disease may respond to hormone therapy, although the complete pathology report still matters.
- ER-low positive results, between 1% and 10%, need careful discussion because the expected benefit of treatment can be less certain.
- At recurrence or metastatic diagnosis, doctors may consider another biopsy because receptor status can differ from the original tumour.
What ER and PR Tests Measure
Hormones and breast cancer cells
Estrogen and progesterone are natural hormones. Some breast cancer cells have receptors that respond to these hormones. ER testing checks for estrogen receptors, while PR testing checks for a progesterone receptor.
These tests help identify the cancer’s hormone receptor status. The Canadian Cancer Society explains that hormone receptor testing helps doctors decide whether hormone therapy should be offered as part of care.
Receptor activity can affect cancer cell growth. A positive receptor result does not describe how you feel or predict a guaranteed response. Instead, it gives your cancer specialist information about treatments that may be medically suitable.
How the laboratory gets the tissue sample
ER and PR testing isn’t a blood test. A pathologist examines breast tissue from a tissue sample. It may come from a core needle biopsy, another breast biopsy, or a surgical biopsy.
A fine needle aspiration collects cells rather than a larger tissue specimen. The laboratory may need to confirm whether the aspirate is adequate for IHC. The laboratory commonly uses immunohistochemistry, also called IHC. Special stains attach to receptors in cancer-cell nuclei, allowing the pathologist to see the percentage of cells that stain positive.
If the sample is limited or results are unclear, your team may discuss a repeat core needle biopsy. An additional fine needle aspiration may also be discussed, but it may not provide the same information as a tissue specimen. Your pathology report may state the percentage, staining intensity, and final interpretation.
Ask for copies of your biopsy report, IHC results, scan reports, and treatment notes. Complete records are more useful than a verbal summary during an oncology consultation.
How to Read ER and PR Test Results
ER-positive and PR-positive results
ER-positive and PR-positive breast cancer has both estrogen and progesterone receptors. This is often called hormone receptor-positive or HR-positive breast cancer.
Your team may discuss hormone therapy because it can block hormone signals or lower estrogen levels. Medicines may include aromatase inhibitors or selective estrogen receptor modulators. Surgery, radiotherapy, systemic treatment, or targeted therapy may also be appropriate, depending on the cancer stage and other pathology findings.
ER-positive but PR-negative results
An ER-positive, PR-negative result means the tumour has estrogen receptors but no detectable progesterone receptor. A detectable ER makes the tumour estrogen receptor positive and hormone receptor-positive.
This pattern does not give you one fixed treatment pathway. Tumour grade, HER2 status, lymph nodes, menopausal status, cancer stage, previous medical history, and treatment tolerance all shape decisions about diagnosis and treatment.
ER-low positive results
ER-low positive refers to ER staining in 1% to 10% of tumour cells. The result is technically ER-positive, yet it should be discussed carefully with your oncologist.
The CAP guidance on estrogen and progesterone receptor testing keeps the 1% threshold for positivity but recognises that evidence for endocrine benefit is limited in the ER-low range. PR does not use the ER-low category.
A pathology report may also describe staining intensity and proportion. An Allred score can combine these findings into one measure.
The available specimen can affect interpretation. A core needle biopsy, fine needle aspiration, or surgical biopsy may differ in adequacy and quality. No single method is always superior for receptor testing.
A percentage on an IHC report describes receptor staining. It does not, by itself, state the cancer stage or determine every treatment you will need.
Hormone receptor-negative results
When ER and PR staining are both below 1%, the cancer is hormone receptor negative. Hormone-based treatment is less likely to help in this situation.
Your oncologist may discuss surgery, radiation therapy, immunotherapy, systemic treatment, or other targeted treatments when appropriate. Suitability depends on the full tumour profile, not receptor results alone.
How ER and PR Findings Relate to Breast Cancer Treatment Options
Endocrine Treatment for HR-Positive Breast Cancer
Hormone therapy, also called endocrine therapy, works differently from other systemic treatment. It aims to reduce estrogen stimulation or block its action on cancer cells with hormone receptors.
Tamoxifen is one of the selective estrogen receptor modulators, often called SERMs. Aromatase inhibitors lower estrogen production. Aromatase inhibitors may be considered for some postmenopausal patients, depending on their treatment plan.
Your oncologist may also discuss ovarian suppression, depending on your age, menopausal status, and treatment goals. Side effects, bone health, blood-clot risk, and other medicines all matter. People using aromatase inhibitors may need monitoring for bone health and other treatment-related concerns.
Your team can explain why one option fits your situation better than another. For some cancers, targeted therapy may also be combined with endocrine treatment, depending on the overall pathology and treatment plan.
Why HER2 is reported separately
HER2 status is a different biomarker. It should not be confused with ER or PR. For a fuller explanation, see our guide to HER2 test results in Malaysia. HER2 testing also often starts with IHC, and an IHC result of 2+ may need an in-situ hybridisation test for clarification.
HER2-positive cancer may be treated with anti-HER2 targeted therapy, such as trastuzumab in suitable cases. However, HER2 results must be interpreted alongside hormone receptors, staging scans, lymph nodes, and other pathology findings.
Other treatment decisions still matter
Stage 2 and Stage 3 cancer treatment decisions may involve treatment before surgery, surgery first, or a combination of treatments. For Stage 4 cancer, your team also considers where the cancer has spread, symptoms, previous treatment, and tumour biomarkers.
Some people with hormone receptor-positive, HER2-negative invasive breast cancer may discuss CDK4/6 inhibitors. Suitability depends on stage, biomarkers, prior treatment, and specialist assessment.
Some patients may also discuss tumor profiling tests if the value of chemotherapy is uncertain. This may involve gene expression profiling. CDK4/6 inhibitors may be part of the treatment discussion, but specialist review remains essential.
These tests supplement pathology and cancer staging. They do not replace them.
For a general overview of possible treatment pathways and medical-travel coordination, you can Explore Cancer Treatment Options. Any treatment recommendation must come from your treating oncologist.
When Results Change After Recurrence
Why repeat testing may be discussed
Breast cancer cells can sometimes show different ER, PR, or HER2 results when cancer returns or spreads. This may happen because tumour cells change over time, or because a new tissue sample provides different information.
At recurrence, the Ministry of Health Malaysia guideline supports reassessing ER and PR when this could affect endocrine treatment decisions. If a metastatic site can be biopsied safely and the result may change care, your doctor may recommend it. For a current HR-positive advanced or metastatic profile, an oncologist may discuss treatments such as CDK4/6 inhibitors. This isn’t a recommendation for every patient.
When reports do not match
A difference between the original and recurrent tumour result does not mean a laboratory made an error. Your oncology team may review the original pathology, request a second pathology review, or explain why the newer result carries more weight for current treatment.
Research on primary and recurrent breast cancer receptor status shows that receptor findings can differ between the original and recurrent disease. That is why a current specimen can be useful in selected cases.
Preparing for a Treatment Plan Review or Second Opinion
A cancer second opinion can be reasonable if your pathology is complex, your results are borderline, major surgery has been recommended, or you need more confidence before starting treatment. It may confirm the current plan, explain it more clearly, suggest further testing, or identify another medically appropriate approach.
Bring your pathology report, IHC and HER2 results, biopsy details, imaging discs and reports, treatment summary, medication list, and tissue-slide information if requested. A medical report review is more accurate when the reviewing specialist has complete records.
For practical coordination of records for specialist review, you can Explore Medical Report Review Support. This type of support can help organise information, but it does not replace a pathologist’s or oncologist’s assessment.
If you want another qualified specialist perspective, Explore Cancer Second Opinion Support. Different cancer hospitals may have different breast oncology teams, pathology services, medicine access, treatment costs, waiting times, and technology. Those differences do not mean another hospital or overseas cancer treatment will automatically be more suitable.
Questions to Ask During Your Oncology Consultation
Bring a caregiver or family member if you can. They can help take notes and remember questions after a stressful appointment.
- What are my ER, PR, and HER2 results, including the percentage of staining?
- Is my cancer hormone receptor-positive, and what does that mean for my treatment?
- Do I have an ER-low positive result that needs further explanation?
- How do my tumour size, stage, lymph nodes, HER2 findings, and pathology affect my treatment plan?
- What cancer treatment options are appropriate for my cancer stage and pathology?
- Will I need surgery, chemotherapy, radiation therapy, hormone therapy, targeted therapy, or more than one treatment?
- Would genetic testing for cancer provide useful information in my case?
- Should I consider a cancer treatment plan review before making a major decision?
- What is the estimated cancer treatment cost, expected timeline, and hospital treatment availability?
If you’re considering care outside Malaysia, Explore Overseas Hospital Options for hospital-enquiry and travel coordination support. Your oncologist should remain the source of medical advice about whether an overseas option fits your diagnosis.
Frequently Asked Questions
Does ER-positive breast cancer always need endocrine treatment?
Hormone therapy is commonly considered for ER-positive breast cancer, but treatment decisions are individual. Medicines may include selective estrogen receptor modulators. Your oncologist will consider the cancer stage, tumour size, HER2 status, surgery, other medicines, and your overall health.
Is ER-positive, PR-negative breast cancer more serious?
You cannot determine how serious a cancer is from this pattern alone. It is still hormone receptor-positive because ER is positive. Your oncologist will explain the result alongside grade, stage, lymph nodes, HER2 findings, and imaging.
Can I get a second opinion before treatment begins?
Yes. A second opinion for cancer may help you understand a complex diagnosis or proposed treatment. It should support informed decisions and should not delay urgent care without discussing timing with your treating team.
Can complementary therapies replace hormone therapy?
No. Complementary cancer therapies, such as counselling, exercise guidance, or symptom support, may be discussed alongside evidence-based care. Alternative therapies should never replace prescribed hormone therapy, chemotherapy, radiotherapy, surgery, or other oncology treatment without speaking to your doctor.
A Clear Result Is One Part of Your Care
The ER and PR findings help explain the biology of breast cancer and guide discussions about hormone therapy. They are most useful when read with HER2 status, staging, scans, pathology, and your personal health circumstances.
Keep copies of your reports, ask for plain-language explanations, and take time to understand the recommended plan. Individual clinical assessment remains the basis for treatment decisions.
Medical disclaimer: This article is for general educational information only and may not apply to every patient. It is not medical advice, a diagnosis, or a treatment recommendation. Cancer treatment decisions depend on individual clinical circumstances, and you should consult your own doctor, oncologist, or qualified healthcare professional before making medical decisions.
